Napoleone Ferrara1. 1. Genentech, Inc., 1 DNA Way, South San Francisco, California, USA. nf@gene.com
Abstract
PURPOSE OF REVIEW: Targeting the vascular endothelial growth factor (VEGF) pathway has had a significant impact in the therapy of cancer and intraocular neovascular disorders. Similar to other therapies, inherent/acquired resistance to anti-VEGF drugs may occur in cancer patients, leading to disease recurrence. This review describes recent findings on the role of myeloid cells in refractoriness or/and acquired resistance to such therapies. RECENT FINDINGS: Various myeloid cell types, including tumor-associated macrophages, Tie2-expressing monocytes and neutrophils, have been implicated in tumor angiogenesis. Several cytokines involved in the mobilization and/or proangiogenic effects of these cells represent therapeutic targets. CD11b+Gr1+ myeloid cells have been shown to render tumors refractory to angiogenic blockade by VEGF antibodies. This effect was mediated by the secreted protein Bv8, which is upregulated by granulocyte colony-stimulating factor. SUMMARY: Progress in unraveling proangiogenic mechanisms dependent on various myeloid cell types has expanded our understanding of tumor angiogenesis and has generated a number of potential therapeutic targets.
PURPOSE OF REVIEW: Targeting the vascular endothelial growth factor (VEGF) pathway has had a significant impact in the therapy of cancer and intraocular neovascular disorders. Similar to other therapies, inherent/acquired resistance to anti-VEGF drugs may occur in cancerpatients, leading to disease recurrence. This review describes recent findings on the role of myeloid cells in refractoriness or/and acquired resistance to such therapies. RECENT FINDINGS: Various myeloid cell types, including tumor-associated macrophages, Tie2-expressing monocytes and neutrophils, have been implicated in tumor angiogenesis. Several cytokines involved in the mobilization and/or proangiogenic effects of these cells represent therapeutic targets. CD11b+Gr1+ myeloid cells have been shown to render tumors refractory to angiogenic blockade by VEGF antibodies. This effect was mediated by the secreted protein Bv8, which is upregulated by granulocyte colony-stimulating factor. SUMMARY: Progress in unraveling proangiogenic mechanisms dependent on various myeloid cell types has expanded our understanding of tumor angiogenesis and has generated a number of potential therapeutic targets.
Authors: Courtney A Penn; Kun Yang; Hong Zong; Jae-Young Lim; Alex Cole; Dongli Yang; James Baker; Sascha N Goonewardena; Ronald J Buckanovich Journal: Mol Cancer Ther Date: 2017-11-13 Impact factor: 6.261
Authors: Michael C Schmid; Christie J Avraamides; Philippe Foubert; Yuval Shaked; Sang Won Kang; Robert S Kerbel; Judith A Varner Journal: Cancer Res Date: 2011-09-23 Impact factor: 12.701
Authors: Andrew B Nixon; Herbert Pang; Mark D Starr; Paula N Friedman; Monica M Bertagnolli; Hedy L Kindler; Richard M Goldberg; Alan P Venook; Herbert I Hurwitz Journal: Clin Cancer Res Date: 2013-10-04 Impact factor: 12.531